Financial PerformanceBio-Techne reported better-than-expected financial results for their 3Q25, including revenues of $316.2 million, an increase of 4.2% year-over-year, and increased adjusted earnings of $0.56 as compared to $0.48 one year ago.
Growth In Innovative ProductsLonger-term, demand for Bio-Techne’s innovative products and systems for the cell and gene therapy market should balance out any downturn from decreases in government R&D funding.
Share Repurchase ProgramOperating cash flow was positive in the quarter for Bio-Techne at $41.1 million, helping to maintain cash balances at $140.7 million after dividends, CapEx, and share buybacks, and allow the Company’s Board to authorize a new $500 million share repurchase program.